Psychiatry

News

AbbVie claims key approval for Vraylar in depression

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes

News

J&J builds case for antidepressant Spravato with head-to-hea...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac

News

Largest-ever trial backs psilocybin treatment for depression

The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe depression, according to the largest randomised, controlled trial of the therapy carried out to

News

jason-rosewell-voice-microphone-child-unsplash

Could cancer be diagnosed from the sound of a voice?

A $14 million research project is getting underway in the US to see whether cancer and other diseases can be diagnosed by picking up subtle changes in a person's voice patterns.

News

Axsome bounces back as FDA clears depression drug

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was

News

NICE backs AliveCor's smartphone-linked ECG for NHS use

In draft guidance, NICE has said that AliveCor's ECG recording device should be an option to check or heart disturbances in patients who take antipsychotic medicines.

AbbVie claims key approval for Vraylar in depression

J&J builds case for antidepressant Spravato with head-to-hea...

Largest-ever trial backs psilocybin treatment for depression

Could cancer be diagnosed from the sound of a voice?

Axsome bounces back as FDA clears depression drug

NICE backs AliveCor's smartphone-linked ECG for NHS use

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Psychiatry

Editor's Picks